Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Decoding the enigma of the commander complex: Employing AlphaFold2 to illuminate biological structures

By Brian Buntz | May 12, 2023

commander complex

The Commander complex. [New image from Institute for Molecular Bioscience The University of Queensland]

Machine learning algorithms, such as Alphabet’s neural network-based model AlphaFold2, are steadily transforming medical research, shedding light on complex biological structures. A recent case in point involves research using the technology to explore the Commander complex, a 16-protein complex crucial for cellular protein transport processes. This complex is not only vital for normal cellular function, but it’s also associated with several diseases, making it a potential target for novel therapies. Scientists at the Universities of Bristol and Queensland (Australia) and the Medical Research Council Laboratory of Molecular Biology in Cambridge in the U.K., collaborated on the research.

The renowned journal Cell published the study, titled “Structure of the endosomal Commander complex linked to Ritscher-Schinzel syndrome.”

Navigating the intricacies of the Commander complex

University of Bristol Professor Peter J. Cullen, a lead author of the study alongside Professor Brett Collins (The University of Queensland) and Kerrie McNally (Medical Research Council Laboratory of Molecular Biology, Cambridge), outlined the challenges they encountered and the role of AI in surmounting these: “We first needed to develop insect cell-based multigene expression technology to purify stable recombinant human Retriever and CCC complexes in sufficient amounts for structural analysis.”

The Retriever and CCC complexes are specific protein structures within cells. The Retriever complex is involved in protein retrieval in the cell, assisting with maintaining cellular function. Similarly, the CCC complex, standing for CCDC22, CCDC93 and COMMD complex, also plays a significant role in protein retrieval within the cell. These complexes work together to help maintain the balance and functionality of the cellular protein pool.

The next challenge came from resolving these complexes using cryo-electron microscopy (cryo-EM). “This is where AI, in the form of AlphaFold2, provided invaluable assistance,” Cullen said.

Eventually, they were able to determine a high-resolution structure of the core COMMD ring of the dodecameric CCC complex and its association with the amino-terminal regions of CCDC22 and CCDC93. The term “dodecameric” refers to a structure composed of twelve subunits. In the context of the CCC complex, “dodecameric” describes the twelve-protein structure of the complex.

But they were unable to resolve the extensive coiled-coil regions of CCDC22/CCDC93 — “presumably because of flexibility within the dimeric coiled-coils,” Cullen added. “Furthermore, the 3D resolution of the retriever complex was limited because of an issue with preferred orientation.”

AlphaFold2 continues to make strides in bioinformatics

Since it was launched in July 2021, the protein structure prediction system AlphaFold2 has found an expanding set of applications in bioinformatics. Capable of predicting protein sequences with near-experimental accuracy, AlphaFold2 allows researchers to explore the form and function of proteins, helping unravel the intricacies of biological processes and disease mechanisms.

In the Commander complex research, AlphaFold2 initially facilitated deriving a model of the Retriever heterotrimer, a component of the protein complex. The Retriever heterotrimer, an assembly of three different proteins, forms part of the backbone of the Commander complex. This prediction by AlphaFold2 was a significant breakthrough, as it “nicely fitted into our low resolution cryo-EM envelope,” Cullen explained.

“AlphaFold2 played a crucial role in overcoming these challenges. As Cullen explained, “AlphaFold2 predicted not only the structure of the COMMD ring and the association with CCDC22 and CCDC93 (beautifully consistent with our cryo-EM structure), but also the overall organization of the coiled-coil regions of the CCDC22/CCDC93 heterodimer.”

Cullen went on to note that AlphaFold2 predicted how Retriever bound to the carboxy-terminal coiled-coil regions of CCDC22/CCDC93 to assemble these sub-complexes. “Finally, AlphaFold2 predicted how an additional subunit DENND10, associated to form the complete sixteen subunit Commander complex,” he said. DENND10 is another protein involved in the 16-subunit Commander complex.

Commander complex and disease implications

The Commander complex is involved in normal cellular functioning but also plays a significant role in several diseases. One example is Ritscher-Schinzel syndrome, also known as cranio-cerebello-cardiac (3C) syndrome. This disorder involves growth delays, intellectual disability and heart defects. Mutations in the Commander complex are responsible for the disease as they disrupt normal cellular protein transport. The rare disease affects about one in 1,000,000 people, according to an article in Case Reports in Clinical Medicine.

“Ritscher-Schinzel syndrome is a multi-system developmental disorder,” Cullen said. “The Commander machine functions to orchestrate the sorting and transport of key integral membrane proteins through the endosomal network.” Scientists know of an expanding number of mutations in the protein complex that are behind the disease. “We consider that the disease therefore principally stems from a defect in the efficiency of sorting and transport of key integral membrane proteins for the development of the tissues and organs affected in the syndrome,” Cullen added.

Verifying the Ritscher-Schinzel model

Verifying the functional aspects of their model was another vital aspect of the study. “A key feature of our study is the extensive utilization of site-directed mutagenesis to quantify effects on the assembly of the complexes which we complemented through validating key interactions by atomic-level X-ray crystallography,” Cullen said.

The implications of understanding the Commander complex extend beyond Ritscher-Schinzel syndrome. “We now know what the Commander complex looks like, how it is assembled and how these features are conserved through eukaryotic evolution,” Cullen said. “This gives us, and others, fantastic information for formulating hypotheses as to its functional role within these disease contexts. We are now actively studying some of these questions.”

AI in molecular biology research poised to continue gaining ground

The study exemplifies the potential of AI in molecular biology research. Cullen further explained this point by adding, “AlphaFold2 is providing a revolution in our understanding of protein structure and the structure and assembly of multiprotein complexes.”

“We consider that our analysis of the Commander complex serves as an example of how AI can be incorporated into classical biochemical and cell-based experimentation to provide exciting new insight into the structure of such complexes,” Cullen said.“Indeed, we and others have published initial findings to this effect,” Cullen noted, highlighting the far-reaching implications of their research.


Filed Under: Data science, Genomics/Proteomics, machine learning and AI, Omics/sequencing, Rare disease
Tagged With: AI in healthcare, AlphaFold2, bioinformatics research, commander complex, molecular biology, protein structure prediction, Ritscher-Schinzel syndrome
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Novartis in the Pharma 50
Novartis announces positive phase 3 data for intrathecal gene therapy in older SMA patients
Deep Genomics
Deep Genomics announces key hires, expands operations in Cambridge, Mass.
DNA matrix image
From Novartis to Pfizer: A closer look at novel cell and gene therapy pricing and reimbursement strategies
Dividing cancer cells - 3D illustration
FDA approves pair of therapies for rare pediatric cancers: Novartis’ Lutathera and Day One’s Ojemda
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE